Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
about
A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxaneDown-regulation of Stathmin Is Required for the Phenotypic Changes and Classical Activation of Macrophages.Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionLiposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01.Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.Mdig, a lung cancer-associated gene, regulates cell cycle progression through p27(KIP1).Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma.The effect of downregulation of Stathmin gene on biological behaviors of U373 and U87-MG glioblastoma cells.
P2860
Q34406424-9EDF01E9-B01E-4CAE-A3D0-EBC89D4C40F9Q34441761-B09FD09A-9A86-4BC7-ADE2-14174C3C8682Q35376227-889285E2-8C64-431A-B2C7-812536274A17Q35905393-656D2673-3110-4182-A81C-C1987BD91E3CQ36657315-076B3D43-78A8-4B19-ACA7-8F27B4BB0E8CQ38300347-2DAB4938-1F52-4F93-B69D-73D3EB922DEAQ38708092-F9FB10AE-D434-46A8-BEF4-E637BF659912Q38889885-A120736C-C98C-4C8F-A35D-F51024CC6010Q45916506-69738520-4613-4326-A3BF-9D233B551248Q52869749-0B9028EA-8693-4007-96D9-03F9186BE8C0Q55427270-820F4B78-A1CC-452E-8662-993C9353DE65
P2860
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@ast
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@en
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@nl
type
label
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@ast
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@en
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@nl
prefLabel
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@ast
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@en
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@nl
P2093
P2860
P1476
Silencing kinase-interacting s ...... ptor-expressing breast cancer.
@en
P2093
Ana M Tari
Banu K Arun
Dongwei Zhang
Gabriel N Hortobagyi
Naoto T Ueno
Rene Nieves-Alicea
Tiffany A LaFortune
P2860
P304
P356
10.1158/1535-7163.MCT-10-0362
P577
2010-11-02T00:00:00Z